Credence Genomics

Using Metagenomics
to battle Sepsis & AMR

Using the power of advanced technology and Big Data with machine learning to provide agnostic diagnostics.

At Credence Genomics our platform use the latest technology on our propriety platform to identify and treat sepsis while tackling AMR. A cost effective comprehensive solution which is fast and accurate.

Our Product

Bactfast^®

22,000 bacteria in a single test using our propriety technology. Separation of contaminants commensal allow for increased accuracy. Recommended by by intensivists, infectious disease and microbiologists to tackle any type of bacterial identification in any sample.

Fungifast^®

6,000 fungi in a single test using our propriety technology. Separation of contaminants commensal allow for increased accuracy. Used in both acute on chronic infections and long term chronic infections common in immunosuppressed individuals including transplant patients.

Virfast^®

9000 viruses in a single test both DNA & RNA using our proprietary technology. Ideal for identifying any viral infection across multiple samples. Species and genotypic resolution available for every sample. The only product with the largest screening of viruses in a single test.

digitalABST^®

Machine learning application to using the output from Bactfast to provide detailed antiobiotic resistance based on identified species.

The technique allows an ICU to very quickly get a comprehensive view of resistance and provide accurate treatment.

Case Studies

Detection of bacterial pathogens from clinical specimens using conventional microbial culture and 16S metagenomics: a comparative study

Metagenomics based results show a 91.8% concordance rate for culture positive specimens and 52.8% concordance rate with culture negative samples. 10.3% of specimens were also positive for fungal species which was not investigated by culture. Specificity and sensitivity for metagenomics analysis is 91.8 and 52.7% respectively.

Conclusion
16S based metagenomic identification of bacterial species within a clinical specimen is on par with conventional culture based techniques and when coupled with clinical information can lead to an accurate diagnostic tool for infectious disease diagnosis.

ICU care through NGS – Based identification of infectious agents: A comparative study

Utilization of Bactfast^® in an ICU setting has shown advantages of NGS based pathogen identification in sepsis. A comprehensive clinical history with site and sample information is important for establishing possible commensal, and contaminant competition. Bactfast^® results can be generated within 36 h, and provides data on the full spectrum of microbial species within a sample including anaerobic, and slow growing organisms. This is especially important in cases where culture, and other testing methods may have limited sensitivity or provide ambiguous results as Bactfast^® will still provide information on pathogen by taking…

Bactfast^®: A Rapid NGS diagnostic tool for Invasive Pneumococcal Disease (IPD) in pediatric ICU and surveillance of streptococcus pneumoniae serotypes for vaccine epidemiology

Total 120 patients were screened from Nov 2022 -May2023. A total of 46 were included in the study. All except 6 participants had received at least 1 dose of the pneumococcal vaccine. Streptococcus pneumoniae was detected in all study participants. Blood culture was negative in all participants except 2. After S. pneumoniae was detected, further analysis was carried out to identify serotypes present using sequenced data. Multiple serotype infection was reported in 52.1% of the patients, with serotype 14 and 4 showing the highest incidence. Non-vaccine serotypes 2, 6C, 11A, 33B and 35F was detected in only 28.2% of patients.

Client Testimonials

DNA Solution Ltd. is proudly working with Credence Genomics for over 2 years introducing their products in Bangladesh. The country’s healthcare needs a comprehensive solution to tackle the sepsis and AMR crisis. The suite of infectious disease products Bactfast^®, Fungifast^®, Virfast^®, & digitalABST^® provides a response to tackle the impending crisis of pathogen identification and effective antibiotic management. Collaboratively we can make a positive impact in the Bangladesh infectious disease response spectrum.

Dr. Mohammad Fazle Alam Rabbi

Assistant Professor – University of Dhaka
Scientific Adviser – DNA Solution

Clinical microbiology has evolved with the advent of new technology such as next generation sequencing. Metagenomics is now widely used to identify organisms based on NGS data . Credence Genomics as a forerunner in the space has developed Bactfast^® and Fungifast^® which is now used in clinical workflow to identify organisms in scenarios where conventional testing faces challenges. The Credence Genomics infectious disease portfolio adds clinical utility and is an added tool in clinical microbiology response.

Dr Nandini Sethuraman, M.D

Sr Consultant and Head,
Department of Microbiology – Apollo Hospitals

Over the last 10 years we have seen the evolution of advanced diagnostic techniques to tackle infectious diseases including next generation sequencing. Credence Genomics have developed Bactfast^® and Fungifast^® which have been able to harness NGS and separate out the relevant data applicable for a clinician’s management. In a world where sepsis and AMR seem to be dominant, clinical healthcare tools like Bactfast^® & Fungifast^® will make a difference.

DR. V RAMASUBRAMANIAN

Senior Consultant in Infectious Diseases, HIV & Tropical Medicine at Apollo Hospital, Chennai
Professor of Infectious Diseases at the Sri Ramachandra Medical Centre and the MGR Medical University
Founder – Capstone Multispeciality Clinic
Chairman of the Polio plus Committee, Rotary Club of Madras,
Past President – Clinical Infectious Diseases Society, India

Our Technology

REPRODUCIBLE PATHOGEN IDENTIFICATION

Credence Genomics infectious disease platform is able to create a reproducible result of extremely high precision. Bactfast^® & Fungifast^® are CE-IVD certified. The multi sample platform is a comprehensive solution in ICU sepsis.

FIND OUT MORE

REPRODUCIBLE PATHOGEN IDENTIFICATION

FIND OUT MORE

MULTI-LAYERED QUALITY CONTROL & VALIDATION

Quality and Validation steps across wet lab and dry lab is conducted over 5 steps. Integrated propriety protocols allow for comprehensive quality delivery in every sample.

FIND OUT MORE

BIG DATA & MACHINE LEARNING

Using machine learning and big data techniques Credence Genomics is able to accurately identify a pathogen while demarcating commensal & contaminant and provide precise antibiotic resistance .

FIND OUT MORE